Minerva Neurosciences, Inc.
NERV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.06 | 0.01 | 0.00 |
| FCF Yield | -116.35% | -36.95% | -290.46% | -71.87% |
| EV / EBITDA | 9.20 | -3.74 | -1.87 | 0.51 |
| Quality | ||||
| ROIC | -63.68% | -43.17% | -57.04% | -58.93% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | -13.59 | 0.49 | 0.77 | 0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | -32.23% | 40.05% | -0.24% | 27.26% |
| Safety | ||||
| Net Debt / EBITDA | 6.41 | -1.89 | -1.52 | 1.18 |
| Interest Coverage | -4.79 | -2.79 | -3.41 | -7.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -0.00 | 0.00 |
| Cash Conversion Cycle | -26,118.79 | -21,268.54 | -170,940.09 | -6,645.55 |